Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987726 · ClinicalTrials.gov registry record
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 150
- Enrollment target
NCT01987726 is a clinical trial that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 150 participants.
The verdict
NCT01987726 has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
This pilot clinical trial studies comprehensive gene sequencing in guiding treatment recommendations in patients with metastatic or recurrent solid tumors. Studying samples of blood and tissue from patients with cancer in the laboratory may improve the ability to plan treatment.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-09-03 |
| Est. Completion | 2021-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01987726
The ClinicalTrials.gov registry entry for NCT01987726 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01987726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01987726 about?
NCT01987726 is a clinical study titled "Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors". This pilot clinical trial studies comprehensive gene sequencing in guiding treatment recommendations in patients with metastatic or recurrent solid tumors. Studying samples of blood and tissue from patients with cancer in the laboratory may improve the ability to plan treatment.
What is the current status of trial NCT01987726?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2013-09-03. Estimated completion is 2021-06-28.
What interventions are being tested in trial NCT01987726?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER).
Who is sponsoring clinical trial NCT01987726?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.